World’s First Personalised mRNA Vaccine for Melanoma Undergoing Trials
The world’s first personalised mRNA vaccine for melanoma, known as mRNA-4157 (V940), developed by Moderna and Merck Sharp & Dohme (MSD), is advancing into Phase III trials in the UK. This innovative vaccine is tailored to each patient’s unique tumor genetic signature, working in conjunction with pembrolizumab (Keytruda) to boost the immune response against cancer cells. Early results are promising, showing a significant reduction in the risk of death or recurrence of melanoma. This vaccine not only holds potential for treating melanoma but is also being tested for other cancer types, possibly revolutionizing cancer treatment and significantly improving survival rates.
